Aarhus University Seal / Aarhus Universitets segl

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • J Ring, Dept Dermatology Allergy Biederstein, Tech Univ Munich, Technical University of Munich, University of Munich, Dept Dermatol & Allergol
  • ,
  • M Worm, Allergy-Center Charité, Charité University Hospital, Berlin, Germany.
  • ,
  • A Wollenberg, Ludwig-Maximilian-University Munich
  • ,
  • J P Thyssen, Bispebjerg Hospital, Bispebjerg
  • ,
  • T Jakob, University Hospital Gießen and Marburg
  • ,
  • L Klimek, Rhinology/Allergy, Medical Faculty Mannheim, Heidelberg University,  Center for Rhinology and Allergology, Wiesbaden, Germany.
  • ,
  • C Bangert, Dermatology dept., Aarhus university Hospital
  • ,
  • S Barbarot, INRAE
  • ,
  • T Bieber, Institute of Human Genetics, School of Medicine & University Hospital Bonn, University of Bonn, Bonn 53127, Germany; Department of Genomics, Life & Brain Center, University of Bonn, Bonn 53127, Germany.
  • ,
  • M S de Bruin-Weller, Department of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Utrecht, Utrecht, The Netherlands; Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands; Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: ent-research@umcutrecht.nl.
  • ,
  • P V Chernyshov, Kazakh National Medical University
  • ,
  • S Christen-Zaech, CHU Vaudois, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Dept Oncol
  • ,
  • M Cork, The University of Sheffield
  • ,
  • U Darsow, Tech Univ Munich, Technical University of Munich, University of Munich, Dept Dermatol & Allergol
  • ,
  • C Flohr, King's College London, Department of Primary Care and Public Health Sciences, London, and NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust, London.
  • ,
  • R Fölster-Holst, University Hospital Schleswig-Holstein
  • ,
  • C Gelmetti, University of Milan, Milan, Italy
  • ,
  • U Gieler, University Hospital Gießen and Marburg
  • ,
  • J Gutermuth, Free University of Brussels (VUB)
  • ,
  • A Heratizadeh, Hannover Unified Biobank, Hannover Medical School, Hannover, 30625, Germany.
  • ,
  • D J Hijnen, Erasmus University Medical Center Cancer Institute, Department of Obstetrics and Gynaecology, Erasmus University Medical Center.
  • ,
  • L B von Kobyletzki, Department of Nephrology in Lund, Clinical Sciences Lund, Skåne University Hospital and Lund University, Lund, Sweden.
  • ,
  • B Kunz, Dermatologikum, Hamburg, Germany.
  • ,
  • C Paul, IMFT UMR 5502, Université de Toulouse og Toulouse University Hospital, Toulouse
  • ,
  • L De Raeve, Free University of Brussels (VUB)
  • ,
  • Julien Seneschal, Inserm, Centre Inserm U897 - Epidémiologie - Biostatistiques, University of Bordeaux, Bordeaux, France; University of Bordeaux, ISPED, Centre Inserm U897 - Epidémiologie - Biostatistiques, Bordeaux, France; Sophie.Desmonde@isped.u-bordeaux2.fr.
  • ,
  • D Simon, Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; and.
  • ,
  • P I Spuls, Department of Dermatology. Amsterdam Public Health/Infection and Immunology
  • ,
  • J F Stalder, INRAE
  • ,
  • A Svensson, Skane Univ Hosp, Lund University, Skane University Hospital, Dept Pediat, Malmö University Hospital, Malmö
  • ,
  • Z Szalai, Pál National Children's Institute Budapest
  • ,
  • A Taieb, Inserm, Centre Inserm U897 - Epidémiologie - Biostatistiques, University of Bordeaux, Bordeaux, France; University of Bordeaux, ISPED, Centre Inserm U897 - Epidémiologie - Biostatistiques, Bordeaux, France; Sophie.Desmonde@isped.u-bordeaux2.fr.
  • ,
  • A Torrelo, Hospital Infantil Universitario Nino Jesus de Madrid
  • ,
  • M Trzeciak, Med Univ Gdansk, Medical University Gdansk
  • ,
  • E.M. Vestergaard, Orthopaedic Research Unit, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark; Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus N, Denmark.
  • ,
  • T Werfel, Hannover Unified Biobank, Hannover Medical School, Hannover, 30625, Germany.
  • ,
  • S Weidinger, University Hospital Schleswig-Holstein
  • ,
  • M Deleuran

Since the introduction of active vaccination against SARS-CoV-2 infection, there has been a debate about the risk of developing severe allergic or anaphylactic reactions among individuals with a history of allergy. Indeed, rare cases of severe allergic reactions have been reported in the United Kingdom and North America. By february 2021 a rate of 4,5 severe allergic reactions occurred among 1 million patients vaccinated with the mRNA-based COVID-19 vaccines, which is higher than the generally expected rate of severe allergic reactions to vaccinations of around 1 in 1 million.

OriginalsprogEngelsk
TidsskriftJournal of the European Academy of Dermatology and Venereology : JEADV
ISSN0926-9959
DOI
StatusE-pub ahead of print - 22 mar. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 213754509